Clinical Trial Update: A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension [Phase 2]

View source ↗

Summary

Phase 2 study of IDN-6556 (emricasan) in patients with cirrhosis and portal hypertension completed; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Portal Hypertension

Drugs mentioned

• IDN-6556

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Liver Cirrhosis, Hepatic Cirrhosis | Phase 2 | Status: COMPLETED | Results posted: 2016-12-21